Novartis Investigative Site

Chiba, Chiba 2608677

3 studies enrolling now · 10 studies all time

What they study most

Active Dermatomyositis, Carcinoma, Chronic Heart Failure, Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD), Generalized Myasthenia Gravis, Hemodialysis, Metastatic Renal Cell Carcinoma, Renal Replacement Therapy, Renal Transplantation, Rheumatoid Arthritis

Studies at this site

• A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis — Recruiting now
• Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis — Recruiting now
• A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. — Recruiting now
• Safety and Efficacy of BAF312 in Dermatomyositis — Stopped early
• Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) — Completed
• Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents — Completed
• Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure — Completed
• Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma. — Completed
• Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma — Completed
• RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib — Completed